(Q47961539)

7 February 2018

title

Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine (English)

1 reference

7 February 2018

1 reference

1 reference

5

1 reference

7 February 2018

author name string

Brynne N

1

1 reference

7 February 2018

Dalén P

2

1 reference

7 February 2018

Alván G

3

1 reference

7 February 2018

Bertilsson L

4

1 reference

7 February 2018

language of work or name

English

0 references

publication date

1 May 1998

1 reference

7 February 2018

Clinical Pharmacology & Therapeutics

published in

1 reference

7 February 2018

volume

63

1 reference

7 February 2018

issue

5

1 reference

7 February 2018

page(s)

529-539

1 reference

7 February 2018

Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990104-7

Clinical consequences of polymorphic drug oxidation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990104-7

Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990104-7

Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990104-7

7 January 2021

Drug therapy. Encainide

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990104-7

Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990104-7

Tolterodine--a new bladder-selective antimuscarinic agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990104-7

Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990104-7

Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990104-7

Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990104-7

Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990104-7

Little anticholinergic effect of E-10-hydroxynortriptyline compared with nortriptyline in healthy subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990104-7

Determination of tolterodine and the 5-hydroxymethyl metabolite in plasma, serum and urine using gas chromatography-mass spectrometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990104-7

The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990104-7

Steady-state plasma levels of clomipramine and its metabolites: impact of the sparteine/debrisoquine oxidation polymorphism. Danish University Antidepressant Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990104-7

The relationship between paroxetine and the sparteine oxidation polymorphism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990104-7

Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990104-7

Debrisoquine oxidation phenotype during neuroleptic monotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990104-7

10.1016/S0009-9236(98)90104-7

7 January 2021

Identifiers

DOI

1 reference

7 February 2018

1 reference

7 February 2018